When Therapeutic Plasma Exchange Supports Hematology & Oncology Care

Chemotherapy and targeted therapies address the underlying malignancy — but some hematology/oncology patients require immediate intervention for the complications their disease creates in the bloodstream.

That’s where Therapeutic Plasma Exchange (TPE) can play a critical role.

TPE rapidly removes harmful circulating plasma components, including paraproteins, autoantibodies, and immune complexes. In hematology and oncology, it’s commonly used for conditions such as hyperviscosity syndrome, thrombotic thrombocytopenic purpura (TTP), and select severe autoimmune hemolytic anemia (AIHA) cases.

Hyperviscosity Syndrome

In disorders like Waldenström macroglobulinemia and multiple myeloma, elevated serum proteins can impair circulation and quickly become symptomatic.

Patients may present with:

• neurologic symptoms

• blurred vision

• mucosal bleeding

• dyspnea

While systemic therapy treats the malignancy, plasma exchange can rapidly reduce serum viscosity and stabilize the patient.

TTP

TTP remains one of the most urgent indications for plasma exchange.

TPE removes inhibitory antibodies while replacing deficient ADAMTS13 activity, helping interrupt ongoing microvascular thrombosis. Early intervention remains critical to reducing morbidity and mortality.

AIHA

In select severe or refractory AIHA presentations, TPE may be used adjunctively to reduce circulating antibodies while immunosuppressive therapies take effect.

Outpatient TPE in Michigan

For hematology and oncology practices, outpatient plasma exchange can improve treatment access, reduce scheduling delays, and provide continuity for patients requiring ongoing apheresis support.

Our Michigan-based therapeutic apheresis team works directly with referring physicians to coordinate timely, evidence-based TPE care for ASFA-supported indications.